Journal of Pharmaceutical Care & Health Systems
Open Access
ISSN: 2376-0419
+44 1300 500008
ISSN: 2376-0419
+44 1300 500008
Ahmed Radwan
Pioneera HealthCare Group, Egypt
Herriot Watt University, UK
Posters & Accepted Abstracts: J Pharma Care Health Sys
There are currently more biosimilar drugs in development across the Asia-Pacific region than anywhere else in the world, leading to several great opportunities. Biosimilar producers in Asian countries share advantages over their competitors in EU & US markets. Biologics are greatly underused across the Asia-Pacific region. Their high cost and the limited reimbursement keep them out of reach for many patients. Biosimilars provide lower-cost alternatives, enabling important biological medicines to be affordable for much more patients. Substituting lower-cost biosimilars for branded biologics would greatly help to lower the governments� healthcare costs on one hand and also increase the patients� access to potentially life-saving drugs on the other hand. Both, governments and patients are counting on biosimilars. Biosimilars could revolutionize the future of drug development in Asian countries. This new drugs are expected to reach globally to $25 billion by 2020. Biosimilars represent a great opportunity for emerging Asian economies to build up domestic biologics and biotechnology capabilities. Domestic and regional biosimilar manufacturers in Asian emerging markets can assume the global leadership role in the near future. This presentation will highlight biosimilars great importance, potential challenges, and huge opportunities for Asian countries and concluded by recommending strategies to help future success.
Email: ahmed.radwan@pioneerahc.com